Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)
Tom Powles, Director of Barts Cancer Centre, shared on Twitter:
“Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached.
Tox was in line with expectations. Grade 3-5 TRAEs in 56% vs 70% for EVP and chemo respectively. 21% of EVP patients discontinuing for adverse events. G3+ skin tox and peripheral neuropathy occurred in 8% and 4% with no Grade 5. EVP tox is different from chemo but not worse.
Overall EVP looks transformative, superseding chemo/IO approaches. It’s attractive for patients and will hopefully get approved for use in the near future. Huge thanks to the research team and the patients.”
Source: Tom Powles/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023